• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Taiwan·Healthcare·4170.TWO
Share

VBI Stocks

NT$ 12.9Last Updated 28.07.2026

Issuer Rating

3/7
Performance

Favourable

Risk

High

Recommendation

Sell

Market Cap

NT$ 19.37M

NT$ 12.9
Key Takeaways

Risk factor

Very poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Vectorite Biomedical Inc., established in 1993 and based in New Taipei City, Taiwan, is a biotechnology firm dedicated to research and development activities globally, including a strong presence in its home country. The company's operations encompass the manufacturing of specialized cell preparation products, in addition to providing full-spectrum services for the collection, processing, and secure storage management of immune cells. These advanced cellular preparations are vital for applications in the medical fields of infectious diseases, inflammatory conditions, and various oncological and tumor-related illnesses.

Company Valuation

Undervalued
6/7

From both historical and forecast perspectives, the stock is underpriced compared to similar stocks. In particular, the stock is underpriced on P/E.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

29.07.2026 15:27

Morning in New York: The Market Awaits a Turning Point

29.07.2026 14:40

Shares of the company in which Trump's son has invested soared 20%. It will sell part of the business

29.07.2026 14:27

SK hynix shares fell 10% following the announcement of a record quarter. What spooked the market?

29.07.2026 13:30

"There's a stock exchange, but virtually no capital market": Why $13 billion Was Withdrawn from Kazakhstan

29.07.2026 12:40

Oninvest Index: Space-Sector Small-Cap Stocks Have Lost Their Half-Year Gains. What's Next?

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026